(210) | Number of the EPO application | 15832711 |
(220) | Filing date of the EPO application | 2015.12.23 |
(80) | EPO patent specification publication (B) | EPB nr. 51/2018, 2018.12.19 |
(110) | EPO patent number | 3237398 |
(21) | Number of the application | e 2017 0238 |
(71) | Name(s) of applicant(s), code of the country | Gilead Sciences, Inc., US; Institute of Organic Chemistry
and Biochemistry AS CR, V.V.I., CZ; |
(72) | Name(s) of inventor(s), code of the country | JANSA Petr, US; SIMON Petr, CZ; LANSDON Eric, US; HU Yunfeng Eric, US; BASZCZYNSKI Ondrej, CZ; DEJMEK Milan, CZ; MACKMAN Richard L., US; |
(73) | Name(s) of owner(s), code of the country | GILEAD Sciences Inc., US; INSTITUTE of Organic Chemistry
and Biochemistry AS CR V.V.I., CZ; |
(54) | Title of the invention | QUINAZOLINE DERIVATIVES USED TO TREAT HIV |
(13) | Kind-of-document code | A1 |
(51) | International Patent Classification | C07D 401/12 (2006.01.01); C07D 239/94 (2006.01.01); A61K 31/517 (2006.01.01); A61P 31/18 (2006.01.01) |
(19) | Country | US |
(41) | Date of publication of the application | 2018.01.31 |
(30) | Priority | 201462096748 P, 2014.12.24, US |
(86) | International application | PCT/US2015/000460, 2015.12.23 |
(87) | International publication | WO 2016/105564, 2016.06.30 |